haloperidol

Ligand id: 86

Name: haloperidol

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: haloperidol

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 40.54
Molecular weight 375.14
XLogP 4.5
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Egan CT, Herrick-Davis K, Teitler M. (1998)
Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
J Pharmacol Exp Ther286: 85-90. [PMID:9655845]
2. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G. (1994)
Expression and pharmacological characterization of the human D3 dopamine receptor.
J Pharmacol Exp Ther268: 417-426. [PMID:8301582]
3. Gessner G, Heinemann SH. (2003)
Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241.
Br. J. Pharmacol.138 (1): 161-71. [PMID:12522086]
4. Jasper JR, Kosaka A, To ZP, Chang DJ, Eglen RM. (1997)
Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b).
Br J Pharmacol122: 126-132. [PMID:9298538]
5. Kobayashi T, Ikeda K, Kumanishi T. (2000)
Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.
Br. J. Pharmacol.129 (8): 1716-22. [PMID:10780978]
6. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A. (1996)
Iloperidone binding to human and rat dopamine and 5-HT receptors.
Eur J Pharmacol317: 417-423. [PMID:8997630]
7. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. (2003)
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Neuropsychopharmacology28: 519-526. [PMID:12629531]
8. Lahti RA, Evans DL, Stratman NC, Figur LM. (1993)
Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications.
Eur J Pharmacol236: 483-486. [PMID:8102973]
9. Lejeune F, Newman-Tancredi A, Audinot V, Millan MJ. (1997)
Interactions of (+)- and (-)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats.
J Pharmacol Exp Ther280: 1241-1249. [PMID:9067310]
10. MacKenzie RG, VanLeeuwen D, Pugsley TA, Shih YH, Demattos S, Tang L, Todd RD, O'Malley KL. (1994)
Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
Eur J Pharmacol266: 79-85. [PMID:7907989]
11. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM. (1995)
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Eur J Pharmacol290: 29-36. [PMID:7664822]
12. Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G. (1998)
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
J Pharmacol Exp Ther286: 1341-1355. [PMID:9732398]
13. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, Audinot V, Millan MJ. (1998)
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
Eur J Pharmacol355: 245-256. [PMID:9760039]
14. Plassat JL, Amlaiky N, Hen R. (1993)
Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase.
Mol Pharmacol44: 229-236. [PMID:8394987]
15. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR. (1994)
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
J Pharmacol Exp Ther268: 1403-1410. [PMID:7908055]
16. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC. (1993)
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
Proc Natl Acad Sci U S A90: 8547-8551. [PMID:8397408]
17. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996)
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.
Psychopharmacology (Berl)124: 57-73. [PMID:8935801]
18. Shahid M, Walker GB, Zorn SH, Wong EH. (2009)
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
J. Psychopharmacol. (Oxford)23 (1): 65-73. [PMID:18308814]
19. Sokoloff P, Andrieux M, Besançon R, Pilon C, Martres M-P, Giros B, Schwartz J-C. (1992)
Pharmacology of human D3 dopamine receptor expressed in a mammalian cell line : comparison with D2 receptor.
Eur. J. Pharmacol.225: 331-337. [PMID:1354163]
20. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. (1990)
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Nature347: 146-151. [PMID:1975644]
21. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HH, Niznik HB. (1991)
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
Nature350: 614-619. [PMID:1826762]
22. Tice MA, Hashemi T, Taylor LA, Duffy RA, McQuade RD. (1994)
Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes.
Pharmacol. Biochem. Behav.49 (3): 567-71. [PMID:7862709]
23. Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, Andersson CM, Tolf BR, Brann MR, Hacksell U, Davis RE. (2004)
Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-aceta mide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
J Pharmacol Exp Ther310: 943-951. [PMID:15102927]
24. Wainscott DB, Sasso DA, Kursar JD, Baez M, Lucaites VL, Nelson DL. (1998)
[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor.
Naunyn Schmiedebergs Arch Pharmacol357: 17-24. [PMID:9459568]